Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute respiratory distress syndrome
Biotech
Kyorin's $140M deal for Japan rights to Edesa respiratory drug
Kyorin Pharmaceutical is paying $12 million upfront for the Japan rights to Edesa Biotech’s anti-TLR4 antibody to treat acute respiratory distress syndrome.
James Waldron
Nov 9, 2026 7:29am
Nano24’s exosome therapy reduces respiratory failure in ph. 2
Oct 20, 2026 7:00am
Edesa claims survival win for phase 3 respiratory failure trial
Oct 28, 2025 9:45am
Tweaking this ventilator setting may protect from lung injury
Aug 22, 2024 12:32pm
Bayer halts respiratory distress drug in phase 2 cleanout
Aug 8, 2023 9:40am
